Antituberculosis agents: Beyond medicinal chemistry rules

WHO Falzon, 2011, WHO Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis: 2011 Update, Eur. Respir. J., 38, 516, 10.1183/09031936.00073611 Mitchison, 1979, Basic Mechanisms of Chemotherapy, Chest, 76, 771, 10.1378/chest.76.6.771 Mitchison, 1985, The Action of Antituberculosis Drugs in Short-Course Chemotherapy, Tubercle, 66, 219, 10.1016/0041-3879(85)90040-6 Caño-Muñiz, 2018, New Approaches and Therapeutic Options for Mycobacterium Tuberculosis in a Dormant State, Clin. Microbiol. Rev., 31, e00060, 10.1128/CMR.00060-17 Tacconelli, 2018, Discovery, Research, and Development of New Antibiotics: The WHO Priority List of Antibiotic-Resistant Bacteria and Tuberculosis, Lancet Infect. Dis., 18, 318, 10.1016/S1473-3099(17)30753-3 Uplekar, 2015, WHO's New End TB Strategy, Lancet, 385, 1799, 10.1016/S0140-6736(15)60570-0 Vjecha, 2018, Accelerating the Development of Therapeutic Strategies for Drug-Resistant Tuberculosis, Nat. Rev. Drug Discov., 17, 607, 10.1038/nrd.2018.28 Laughon, 2017, Tuberculosis—Drugs in the 2016 Development Pipeline, Nat. Rev. Dis. Primers., 3, 17015, 10.1038/nrdp.2017.15 Cole, 1998, Deciphering the Biology of Mycobacterium tuberculosis from the Complete Genome Sequence, Nature, 393, 537, 10.1038/31159 Fischbach, 2009, Antibiotics for Emerging Pathogens, Science, 325, 1089, 10.1126/science.1176667 Payne, 2007, Drugs for Bad Bugs: Confronting the Challenges of Antibacterial Discovery, Nat. Rev. Drug Discov., 6, 29, 10.1038/nrd2201 Lechartier, 2014, Tuberculosis Drug Discovery in the Post-Post-Genomic Era, EMBO Mol. Med., 6, 158, 10.1002/emmm.201201772 Jarlier, 1994, Mycobacterial Cell Wall: Structure and Role in Natural Resistance to Antibiotics, FEMS Microbiol. Lett., 123, 11, 10.1111/j.1574-6968.1994.tb07194.x Favrot, 2012, Targeting the Mycobacterial Envelope for Tuberculosis Drug Development, Expert Rev. Anti Infect. Ther., 10, 1023, 10.1586/eri.12.91 Bacon, 2014, Non-Replicating Mycobacterium Tuberculosis Elicits a Reduced Infectivity Profile With Corresponding Modifications to the Cell Wall and Extracellular Matrix, PLoS One, 9, 10.1371/journal.pone.0087329 Daniel, 2014, An Acyl-CoA Synthetase in Mycobacterium Tuberculosis Involved in Triacylglycerol Accumulation during Dormancy, PLoS One, 9, 10.1371/journal.pone.0114877 Seiler, 2003, Cell-Wall Alterations as an Attribute of Mycobacterium Tuberculosis in Latent Infection, J Infect Dis, 188, 1326, 10.1086/378563 Dartois, 2014, The Path of Anti-Tuberculosis Drugs: From Blood to Lesions to Mycobacterial Cells, Nat. Rev. Microbiol., 12, 159, 10.1038/nrmicro3200 Piccaro, 2015, Activity of Lipophilic and Hydrophilic Drugs against Dormant and Replicating Mycobacterium Tuberculosis, J. Antibiot. (Tokyo), 68, 711, 10.1038/ja.2015.52 Hansch, 1987, Hydrophobicity and Central Nervous System Agents: On the Principle of Minimal Hydrophobicity in Drug Design, J. Pharm. Sci., 76, 663, 10.1002/jps.2600760902 Lipinski, 1997, Experimental and Computational Approaches to Estimate Solubility and Permeability in Drug Discovery and Development Settings, Adv. Drug Deliv. Rev., 23, 3, 10.1016/S0169-409X(96)00423-1 Veber, 2002, Molecular Properties That Influence the Oral Bioavailability of Drug Candidates, J. Med. Chem., 45, 2615, 10.1021/jm020017n Gleeson, 2008, Generation of a Set of Simple, Interpretable ADMET Rules of Thumb, J. Med. Chem., 51, 817, 10.1021/jm701122q Doak, 2014, Oral Druggable Space Beyond the Rule of 5: Insights From Drugs and Clinical Candidates, Chem. Biol., 21, 1115, 10.1016/j.chembiol.2014.08.013 Hoagland, 2016, New Agents for the Treatment of Drug-Resistant Mycobacterium Tuberculosis, Adv. Drug Deliv. Rev., 102, 55, 10.1016/j.addr.2016.04.026 van der Westhuyzen, 2015, Pyrrolo[3,4-c]Pyridine-1,3(2H)-Diones: A Novel Antimycobacterial Class Targeting Mycobacterial Respiration, J. Med. Chem., 58, 9371, 10.1021/acs.jmedchem.5b01542 Ekins, 2011, Computational Databases, Pathway and Cheminformatics Tools for Tuberculosis Drug Discovery, Trends Microbiol., 19, 65, 10.1016/j.tim.2010.10.005 Goldman, 2013, Why Are Membrane Targets Discovered by Phenotypic Screens and Genome Sequencing in Mycobacterium Tuberculosis?, Tuberculosis (Edinb), 93, 569, 10.1016/j.tube.2013.09.003 Mao, 2009, From Serendipity to Rational Antituberculosis Drug Discovery of Mefloquine-Isoxazole Carboxylic Acid Esters, J. Med. Chem., 52, 6966, 10.1021/jm900340a Marco, 2010, NOC Chemistry for Tuberculosis—Further Investigations on the Structure–Activity Relationships of Antitubercular Isoxazole-3-Carboxylic Acid Ester Derivatives, ChemMedChem, 5, 1667, 10.1002/cmdc.201000169 Tabarrini, 2012, 6-Hydrogen-8-Methylquinolones Active Against Replicating and Non-Replicating Mycobacterium Tuberculosis, Chem. Biol. Drug Des., 80, 781, 10.1111/cbdd.12022 Hurdle, 2011, Targeting Bacterial Membrane Function: An Underexploited Mechanism for Treating Persistent Infections, Nat. Rev. Microbiol., 9, 62, 10.1038/nrmicro2474 Andries, 2005, A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium Tuberculosis, Science, 307, 223, 10.1126/science.1106753 Mahajan, 2013, Bedaquiline: First FDA-Approved Tuberculosis Drug in 40 Years, Int. J. Appl. Basic Med. Res., 3, 1, 10.4103/2229-516X.112228 de Jonge, 2007, A Computational Model of the Inhibition of Mycobacterium Tuberculosis ATPase by a New Drug Candidate R207910, Proteins, 67, 971, 10.1002/prot.21376 Koul, 2007, Diarylquinolines Target Subunit c of Mycobacterial ATP Synthase, Nat. Chem. Biol., 3, 323, 10.1038/nchembio884 Sensi, 1983, History of the Development of Rifampin, Rev. Infect. Dis., 3, S402, 10.1093/clinids/5.Supplement_3.S402 Koul, 2008, Diarylquinolines Are Bactericidal for Dormant Mycobacteria as a Result of Disturbed ATP Homeostasis, J. Biol. Chem., 283, 25273, 10.1074/jbc.M803899200 Matsuno-Yagi, 1993, Studies on the Mechanism of Oxidative Phosphorylation. Different Effects of F0 Inhibitors on Unisite and Multisite ATP Hydrolysis by Bovine Submitochondrial Particles, J. Biol. Chem., 268, 1539, 10.1016/S0021-9258(18)53886-2 Haagsma, 2009, Selectivity of TMC207 Towards Mycobacterial ATP Synthase Compared With That Towards the Eukaryotic Homologue, Antimicrob. Agents Chemother., 53, 1290, 10.1128/AAC.01393-08 Guglielmetti, 2017, Long-Term Outcome and Safety of Prolonged Bedaquiline Treatment for Multidrug-Resistant Tuberculosis, Eur. Respir. J., 49, 1601799, 10.1183/13993003.01799-2016 Kakkar, 2014, Bedaquiline for the Treatment of Resistant Tuberculosis: Promises and Pitfalls, Tuberculosis (Edinb.), 94, 357, 10.1016/j.tube.2014.04.001 Fox, 2013, A Review of the Evidence for Using Bedaquiline (TMC207) to Treat Multi-Drug Resistant Tuberculosis, Infect. Dis. Ther., 2, 123, 10.1007/s40121-013-0009-3 Huitric, 2010, Rates and Mechanisms of Resistance Development in Mycobacterium Tuberculosis to a Novel Diarylquinoline ATP Synthase Inhibitor, Antimicrob. Agents Chemother., 54, 1022, 10.1128/AAC.01611-09 Petrella, 2006, Genetic Basis for Natural and Acquired Resistance to the Diarylquinoline R207910 in Mycobacteria, Antimicrob. Agents Chemother., 50, 2853, 10.1128/AAC.00244-06 Andries, 2014, Acquired Resistance of Mycobacterium Tuberculosis to Bedaquiline, PLoS One, 9, 10.1371/journal.pone.0102135 Hartkoorn, 2014, Cross-Resistance Between Clofazimine and Bedaquiline Through Upregulation of MmpL5 in Mycobacterium Tuberculosis, Antimicrob. Agents Chemother., 58, 2979, 10.1128/AAC.00037-14 Molinspiration Pal, 1996, Phototoxicity of Some Bromine-Substituted Rhodamine Dyes: Synthesis, Photophysical Properties and Application as Photosensitizers, Photochem. Photobiol., 63, 161, 10.1111/j.1751-1097.1996.tb03008.x Sutherland, 2018, Structure-Activity Relationships for Analogs of the Tuberculosis Drug Bedaquiline With the Naphthalene Unit Replaced by Bicyclic Heterocycles, Bioorg. Med. Chem., 26, 1797, 10.1016/j.bmc.2018.02.026 Tong, 2017, 6-Cyano Analogues of Bedaquiline as Less Lipophilic and Potentially Safer Diarylquinolines for Tuberculosis, ACS Med. Chem. Lett., 8, 1019, 10.1021/acsmedchemlett.7b00196 Skripconoka, 2013, Delamanid Improves Outcomes and Reduces Mortality in Multidrug-Resistant Tuberculosis, Eur. Respir. J., 41, 1393, 10.1183/09031936.00125812 Gler, 2012, Delamanid for Multidrug-Resistant Pulmonary Tuberculosis, N. Engl. J. Med., 366, 2151, 10.1056/NEJMoa1112433 Matsumoto, 2006, OPC-67683, a Nitro-Dihydro-Imidazooxazole Derivative With Promising Action Against Tuberculosis in Vitro and in Mice, PLoS Med., 3, 10.1371/journal.pmed.0030466 Sotgiu, 2015, Delamanid (OPC-67683) for Treatment of Multi-Drug-Resistant Tuberculosis, Expert Rev. Anti Infect. Ther., 13, 305, 10.1586/14787210.2015.1011127 Harausz, 2015, QTc Prolongation and Treatment of Multidrug-Resistant Tuberculosis, Int. J. Tuberc. Lung Dis., 19, 385, 10.5588/ijtld.14.0335 Bloemberg, 2015, Acquired Resistance to Bedaquiline and Delamanid in Therapy for Tuberculosis, N. Engl. J. Med., 373, 1986, 10.1056/NEJMc1505196 Singh, 2008, PA-824 Kills Nonreplicating Mycobacterium Tuberculosis by Intracellular NO Release, Science, 322, 1392, 10.1126/science.1164571 Agrawal, 1979, Potential Radiosensitizing Agents. Dinitroimidazoles, J. Med. Chem., 22, 583, 10.1021/jm00191a025 Ashtekar, 1993, In Vitro and in Vivo Activities of the Nitroimidazole CGI 17341 Against Mycobacterium Tuberculosis, Antimicrob. Agents Chemother., 37, 183, 10.1128/AAC.37.2.183 Nagarajan, 1989, Nitroimidazoles XXI 2,3-Dihydro-6-Nitroimidazo [2,1-b] Oxazoles With Antitubercular Activity, Eur. J. Med. Chem., 24, 631, 10.1016/0223-5234(89)90034-2 Walsh, 1987, Structural Alterations That Differentially Affect the Mutagenic and Antitrichomonal Activities of 5-Nitroimidazoles, J. Med. Chem., 30, 150, 10.1021/jm00384a025 Stover, 2000, A Small-Molecule Nitroimidazopyran Drug Candidate for the Treatment of Tuberculosis, Nature, 405, 962, 10.1038/35016103 Manjunatha, 2009, The Mechanism of Action of PA-824, Commun. Integr. Biol., 2, 215, 10.4161/cib.2.3.7926 Pethe, 2013, Discovery of Q203, a Potent Clinical Candidate for the Treatment of Tuberculosis, Nat. Med., 19, 1157, 10.1038/nm.3262 Lamprecht, 2016, Turning the Respiratory Flexibility of Mycobacterium Tuberculosis Against Itself, Nat. Commun., 7, 12393, 10.1038/ncomms12393 Jang, 2017, Efflux Attenuates the Antibacterial Activity of Q203 in Mycobacterium Tuberculosis, Antimicrob. Agents Chemother., 61, e02637, 10.1128/AAC.02637-16 Barry, 2004, Prospects for Clinical Introduction of Nitroimidazole Antibiotics for the Treatment of Tuberculosis, Curr. Pharm. Des., 10, 3239, 10.2174/1381612043383214 Boelsterli, 2006, Bioactivation and Hepatotoxicity of Nitroaromatic Drugs, Curr. Drug Metab., 7, 715, 10.2174/138920006778520606 Erve, 2006, Chemical Toxicology: Reactive Intermediates and Their Role in Pharmacology and Toxicology, Expert Opin. Drug Metab. Toxicol., 2, 923, 10.1517/17425255.2.6.923 Kalgutkar, 2005, A Comprehensive Listing of Bioactivation Pathways of Organic Functional Groups, Curr. Drug Metab., 6, 161, 10.2174/1389200054021799 Raether, 2003, Nitroheterocyclic Drugs With Broad Spectrum Activity, Parasitol. Res., 90, S19, 10.1007/s00436-002-0754-9 Rodriguez, 2002, DNA Single Strand Breaks in Peripheral Blood Lymphocytes Induced by Three Nitroimidazole Derivatives, Toxicol. Lett., 132, 109, 10.1016/S0378-4274(02)00039-5 Matsumoto, 2007, Screening for Novel Antituberculosis Agents That Are Effective Against Multidrug Resistant Tuberculosis, Curr. Top. Med. Chem., 7, 499, 10.2174/156802607780059727 Sasaki, 2006, Synthesis and Antituberculosis Activity of a Novel Series of Optically Active 6-Nitro-2,3-Dihydroimidazo[2,1-b]Oxazoles, J. Med. Chem., 49, 7854, 10.1021/jm060957y Boechat, 2015, Studies of Genotoxicity and Mutagenicity of Nitroimidazoles: Demystifying This Critical Relationship With the Nitro Group, Mem. Inst. Oswaldo Cruz, 110, 492, 10.1590/0074-02760140248 Patterson, 2014, Nitro Drugs for the Treatment of Trypanosomatid Diseases: Past, Present, and Future Prospects, Trends Parasitol., 30, 289, 10.1016/j.pt.2014.04.003 Shigyo, 2013, Efficacy of Nitazoxanide Against Clinical Isolates of Mycobacterium Tuberculosis, Antimicrob. Agents Chemother., 57, 2834, 10.1128/AAC.02542-12 Protopopova, 2003 Sacksteder, 2012, Discovery and Development of SQ109: A New Antitubercular Drug With a Novel Mechanism of Action, Future Microbiol., 7, 823, 10.2217/fmb.12.56 Chen, 2006, Synergistic Interactions of SQ109, a New Ethylene Diamine, With Front-Line Antitubercular Drugs in Vitro, J. Antimicrob. Chemother., 58, 332, 10.1093/jac/dkl227 Nikonenko, 2007, Drug Therapy of Experimental Tuberculosis (TB): Improved Outcome by Combining SQ109, a New Diamine Antibiotic, With Existing TB Drugs, Antimicrob. Agents Chemother., 51, 1563, 10.1128/AAC.01326-06 Reddy, 2010, In Vitro Interactions Between New Antitubercular Drug Candidates SQ109 and TMC207, Antimicrob. Agents Chemother., 54, 2840, 10.1128/AAC.01601-09 Heinrich, 2015, Early Phase Evaluation of SQ109 Alone and in Combination With Rifampicin in Pulmonary TB Patients, J. Antimicrob. Chemother., 70, 1558, 10.1093/jac/dku553 Tahlan, 2012, SQ109 Targets MmpL3, a Membrane Transporter of Trehalose Monomycolate Involved in Mycolic Acid Donation to the Cell Wall Core of Mycobacterium Tuberculosis, Antimicrob. Agents Chemother., 56, 1797, 10.1128/AAC.05708-11 Onajole, 2011, SQ109 Analogues as Potential Antimicrobial Candidates, Med. Chem. Res., 20, 1394, 10.1007/s00044-010-9490-3 Li, 2014, Multitarget Drug Discovery for Tuberculosis and Other Infectious Diseases, J. Med. Chem., 57, 3126, 10.1021/jm500131s Li, 2014, Novel Insights Into the Mechanism of Inhibition of MmpL3, a Target of Multiple Pharmacophores in Mycobacterium Tuberculosis, Antimicrob. Agents Chemother., 58, 6413, 10.1128/AAC.03229-14 Li, 2017, Synergistic Interactions of MmpL3 Inhibitors With Antitubercular Compounds In Vitro, Antimicrob. Agents Chemother., 61, e02399, 10.1128/AAC.02399-16 Lee, 2003, Combinatorial Lead Optimization of [1,2]-Diamines Based on Ethambutol as Potential Antituberculosis Preclinical Candidates, J. Comb. Chem., 5, 172, 10.1021/cc020071p Lun, 2013, Indoleamides Are Active Against Drug-Resistant Mycobacterium Tuberculosis, Nat. Commun., 4, 2907, 10.1038/ncomms3907 Onajole, 2013, Preliminary Structure-Activity Relationships and Biological Evaluation of Novel Antitubercular Indolecarboxamide Derivatives Against Drug-Susceptible and Drug-Resistant Mycobacterium Tuberculosis Strains, J. Med. Chem., 56, 4093, 10.1021/jm4003878 Bogatcheva, 2011, Identification of SQ609 as a Lead Compound From a Library of Dipiperidines, Bioorg. Med. Chem. Lett., 21, 5353, 10.1016/j.bmcl.2011.07.015 Bogatcheva, 2006, Identification of New Diamine Scaffolds With Activity Against Mycobacterium Tuberculosis, J. Med. Chem., 49, 3045, 10.1021/jm050948+ Bogatcheva, 2010, Discovery of Dipiperidines as New Antitubercular Agents, Bioorg. Med. Chem. Lett., 20, 201, 10.1016/j.bmcl.2009.10.135 Gerzon, 1963, The Adamantyl Group in Medicinal Agents. I. Hypoglycemic N-Arylsulfonyl-N’-Adamantylureas, J. Med. Chem., 6, 760, 10.1021/jm00342a029 Rapala, 1965, The Adamantyl Group in Medicinal Agents. II. Anabolic Steroid 17β-Adamantoates, J. Med. Chem., 8, 580, 10.1021/jm00329a007 Gerzon, 1967, The Adamantyl Group in Medicinal Agents. III. Nucleoside 5’-Adamantoates. The Adamantoyl Function as a Protecting Group, J. Med. Chem., 10, 189, 10.1021/jm00314a014 Kovtun, 1987, Use of Adamantanecarboxylic Acid for the Modification of Drugs and Biologically Active Compounds (Review), Pharm. Chem. J., 21, 555, 10.1007/BF00759430 Wanka, 2013, The Lipophilic Bullet Hits the Targets: Medicinal Chemistry of Adamantane Derivatives, Chem. Rev., 113, 3516, 10.1021/cr100264t Grzegorzewicz, 2012, Inhibition of Mycolic Acid Transport Across the Mycobacterium Tuberculosis Plasma Membrane, Nat. Chem. Biol., 8, 334, 10.1038/nchembio.794 Rao, 2013, Indolcarboxamide Is a Preclinical Candidate for Treating Multidrug-Resistant Tuberculosis, Sci. Transl. Med., 5, 214ra168, 10.1126/scitranslmed.3007355 Harrison, 2014, Infectious Disease: New Leads for Resistant Tuberculosis, Nat. Rev. Drug Discov., 13, 104 Domenech, 2005, Contribution of the Mycobacterium Tuberculosis MmpL Protein Family to Virulence and Drug Resistance, Infect. Immun., 73, 3492, 10.1128/IAI.73.6.3492-3501.2005 La Rosa, 2012, MmpL3 Is the Cellular Target of the Antitubercular Pyrrole Derivative BM212, Antimicrob. Agents Chemother., 56, 324, 10.1128/AAC.05270-11 Zhang, 2019, Crystal Structures of Membrane Transporter MmpL3, an Anti-TB Drug Target, Cell, 176, 636, 10.1016/j.cell.2019.01.003 Makarov, 2009, Benzothiazinones Kill Mycobacterium Tuberculosis by Blocking Arabinan Synthesis, Science, 324, 801, 10.1126/science.1171583 Trefzer, 2010, Benzothiazinones: Prodrugs That Covalently Modify the Decaprenylphosphoryl-β-d-Ribose 2′-Epimerase DprE1 of Mycobacterium Tuberculosis, J. Am. Chem. Soc., 132, 13663, 10.1021/ja106357w Manina, 2010, Biological and Structural Characterization of the Mycobacterium Smegmatis Nitroreductase NfnB, and Its Role in Benzothiazinone Resistance, Mol. Microbiol., 77, 1172, 10.1111/j.1365-2958.2010.07277.x Chiarelli, 2016, New and Old Hot Drug Targets in Tuberculosis, Curr. Med. Chem., 23, 3813, 10.2174/1389557516666160831164925 Makarov, 2014, Towards a New Combination Therapy for Tuberculosis With Next Generation Benzothiazinones, EMBO Mol. Med., 6, 372, 10.1002/emmm.201303575 Makarov, 2015, The 8-Pyrrole-Benzothiazinones Are Noncovalent Inhibitors of DprE1 From Mycobacterium Tuberculosis, Antimicrob. Agents Chemother., 59, 4446, 10.1128/AAC.00778-15 Diacon, 2015, Bactericidal Activity of Pyrazinamide and Clofazimine Alone and in Combinations With Pretomanid and Bedaquiline, Am. J. Respir. Crit. Care Med., 191, 943, 10.1164/rccm.201410-1801OC Tang, 2015, Clofazimine for the Treatment of Multidrug-Resistant Tuberculosis: Prospective, Multicenter, Randomized Controlled Study in China, Clin. Infect. Dis., 60, 1361 Yang, 2017, Clofazimine-Containing Regimen for the Treatment of Mycobacterium Abscessus Lung Disease, Antimicrob. Agents Chemother., 61, e02052, 10.1128/AAC.02052-16 Hwang, 2014, Safety and Availability of Clofazimine in the Treatment of Multidrug and Extensively Drug-Resistant Tuberculosis: Analysis of Published Guidance and Meta-Analysis of Cohort Studies, BMJ Open, 4, e004143, 10.1136/bmjopen-2013-004143 Zhang, 2014, Synthesis and Biological Evaluation of Novel 2-Methoxypyridylamino-Substituted Riminophenazine Derivatives as Antituberculosis Agents, Mol. Basel Switz., 19, 4380 Zhang, 2012, Identification of Less Lipophilic Riminophenazine Derivatives for the Treatment of Drug-Resistant Tuberculosis, J. Med. Chem., 55, 8409, 10.1021/jm300828h Veziris, 2016, Rapid Emergence of Mycobacterium Tuberculosis Bedaquiline Resistance: Lessons to Avoid Repeating Past Errors, Eur. Respir. J., 49, 1601719, 10.1183/13993003.01719-2016 Wallis, 2015, Advancing Host-Directed Therapy for Tuberculosis, Nat. Rev. Immunol., 15, 255, 10.1038/nri3813 Ordonez, 2014, Novel Adjunctive Therapies for the Treatment of Tuberculosis, Curr. Mol. Med., 14, 385, 10.2174/1566524013666131118112431 Kiran, 2016, Host-Directed Therapy Targeting the Mycobacterium Tuberculosis Granuloma: A Review, Semin. Immunopathol., 38, 167, 10.1007/s00281-015-0537-x Stanley, 2014, Identification of Host-Targeted Small Molecules That Restrict Intracellular Mycobacterium Tuberculosis Growth, PLoS Pathog., 10, 10.1371/journal.ppat.1003946 Singhal, 2014, Metformin as Adjunct Antituberculosis Therapy, Sci. Transl. Med., 6, 263ra159, 10.1126/scitranslmed.3009885 Ravikumar, 2004, Inhibition of MTOR Induces Autophagy and Reduces Toxicity of Polyglutamine Expansions in Fly and Mouse Models of Huntington Disease, Nat. Genet., 36, 585, 10.1038/ng1362 Martineau, 2017, Vitamin D Supplementation to Prevent Acute Respiratory Tract Infections: Systematic Review and Meta-Analysis of Individual Participant Data, BMJ, 356, i6583, 10.1136/bmj.i6583 Bruns, 2012, Abelson Tyrosine Kinase Controls Phagosomal Acidification Required for Killing of Mycobacterium Tuberculosis in Human Macrophages, J. Immunol., 189, 4069, 10.4049/jimmunol.1201538 Kapp, 2018, Small Molecule Efflux Pump Inhibitors in Mycobacterium Tuberculosis: A Rational Drug Design Perspective, Mini Rev. Med. Chem., 18, 72 Dooley, 1997, Adjunctive Corticosteroid Therapy for Tuberculosis: A Critical Reappraisal of the Literature, Clin. Infect. Dis., 25, 872, 10.1086/515543 Byrne, 2007, Aspirin and Ibuprofen Enhance Pyrazinamide Treatment of Murine Tuberculosis, J. Antimicrob. Chemother., 59, 313, 10.1093/jac/dkl486 Wallis, 2004, A Study of the Safety, Immunology, Virology, and Microbiology of Adjunctive Etanercept in HIV-1-Associated Tuberculosis, AIDS, 18, 257, 10.1097/00002030-200401230-00015 Skerry, 2012, Adjunctive TNF Inhibition With Standard Treatment Enhances Bacterial Clearance in a Murine Model of Necrotic TB Granulomas, PLoS One, 7, 10.1371/journal.pone.0039680 Koo, 2011, Phosphodiesterase 4 Inhibition Reduces Innate Immunity and Improves Isoniazid Clearance of Mycobacterium Tuberculosis in the Lungs of Infected Mice, PLoS One, 6, 10.1371/journal.pone.0017091 Subbian, 2011, Phosphodiesterase-4 Inhibition Alters Gene Expression and Improves Isoniazid-Mediated Clearance of Mycobacterium Tuberculosis in Rabbit Lungs, PLoS Pathog., 7, 10.1371/journal.ppat.1002262 Machado, 2012, Contribution of Efflux to the Emergence of Isoniazid and Multidrug Resistance in Mycobacterium Tuberculosis, PLoS One, 7, 10.1371/journal.pone.0034538 Machado, 2017, Interplay Between Mutations and Efflux in Drug Resistant Clinical Isolates of Mycobacterium Tuberculosis, Front. Microbiol., 8, 711, 10.3389/fmicb.2017.00711 Machado, 2018, Efflux Activity Differentially Modulates the Levels of Isoniazid and Rifampicin Resistance Among Multidrug Resistant and Monoresistant Mycobacterium Tuberculosis Strains, Antibiotics (Basel), 7, 18, 10.3390/antibiotics7010018 Machado, 2016, Ion Channel Blockers as Antimicrobial Agents, Efflux Inhibitors, and Enhancers of Macrophage Killing Activity Against Drug Resistant Mycobacterium Tuberculosis, PLoS One, 11, 10.1371/journal.pone.0149326 Adams, 2011, Drug Tolerance in Replicating Mycobacteria Mediated by a Macrophage-Induced Efflux Mechanism, Cell, 145, 39, 10.1016/j.cell.2011.02.022 Adams, 2014, Verapamil, and Its Metabolite Norverapamil, Inhibit Macrophage-Induced, Bacterial Efflux Pump-Mediated Tolerance to Multiple Anti-Tubercular Drugs, J Infect Dis, 210, 456, 10.1093/infdis/jiu095 Viveiros, 2012, Inhibitors of Mycobacterial Efflux Pumps as Potential Boosters for Anti-Tubercular Drugs, Expert Rev. Anti Infect. Ther., 10, 983, 10.1586/eri.12.89 Van Bambeke, 2006, Inhibitors of Bacterial Efflux Pumps as Adjuvants in Antibiotic Treatments and Diagnostic Tools for Detection of Resistance by Efflux, Recent Pat. Antiinfect. Drug Discov., 1, 157, 10.2174/157489106777452692 Bhardwaj, 2012, Bacterial Efflux Pumps Involved in Multidrug Resistance and Their Inhibitors: Rejuvinating the Antimicrobial Chemotherapy, Recent Pat. Antiinfect. Drug Discov., 7, 73, 10.2174/157489112799829710 Amaral, 2014, Efflux Pumps of Gram-Negative Bacteria: What They Do, How They Do It, With What and How to Deal With Them, Front. Pharmacol., 4, 168, 10.3389/fphar.2013.00168 Singh, 2014, Synthesis of New Verapamil Analogues and Their Evaluation in Combination With Rifampicin Against Mycobacterium Tuberculosis and Molecular Docking Studies in the Binding Site of Efflux Protein Rv1258c, Bioorg. Med. Chem. Lett., 24, 2985, 10.1016/j.bmcl.2014.05.022 Sharma, 2010, Piperine as an Inhibitor of Rv1258c, a Putative Multidrug Efflux Pump of Mycobacterium Tuberculosis, J. Antimicrob. Chemother., 65, 1694, 10.1093/jac/dkq186 Pule, 2016, Efflux Pump Inhibitors: Targeting Mycobacterial Efflux Systems to Enhance TB Therapy, J. Antimicrob. Chemother., 71, 17, 10.1093/jac/dkv316 Warman, 2013, Antitubercular Pharmacodynamics of Phenothiazines, J. Antimicrob. Chemother., 68, 869, 10.1093/jac/dks483 Weinstein, 2005, Inhibitors of Type II NADH:Menaquinone Oxidoreductase Represent a Class of Antitubercular Drugs, Proc. Natl. Acad. Sci. U. S. A., 102, 4548, 10.1073/pnas.0500469102 van Soolingen, 2010, The Antipsychotic Thioridazine Shows Promising Therapeutic Activity in a Mouse Model of Multidrug-Resistant Tuberculosis, PLoS One, 5, e12640, 10.1371/journal.pone.0012640 Abbate, 2012, Successful Alternative Treatment of Extensively Drug-Resistant Tuberculosis in Argentina With a Combination of Linezolid, Moxifloxacin and Thioridazine, J. Antimicrob. Chemother., 67, 473, 10.1093/jac/dkr500 Daniel, 2003, Mechanisms of Cellular Distribution of Psychotropic Drugs. Significance for Drug Action and Interactions, Prog. Neuropsychopharmacol. Biol. Psychiatry, 27, 65, 10.1016/S0278-5846(02)00317-2 Kornhuber, 2010, Lipophilic Cationic Drugs Increase the Permeability of Lysosomal Membranes in a Cell Culture System, J. Cell. Physiol., 224, 152 Martins, 2007, In Vitro and Ex Vivo Activity of Thioridazine Derivatives against Mycobacterium Tuberculosis, Int. J. Antimicrob. Agents, 29, 338, 10.1016/j.ijantimicag.2006.10.013 Salie, 2014, Novel Non-Neuroleptic Phenothiazines Inhibit Mycobacterium Tuberculosis Replication, J. Antimicrob. Chemother., 69, 1551, 10.1093/jac/dku036 Pieroni, 2015, Rational Design and Synthesis of Thioridazine Analogues as Enhancers of the Antituberculosis Therapy, J. Med. Chem., 58, 5842, 10.1021/acs.jmedchem.5b00428 Scalacci, 2017, Synthesis and SAR Evaluation of Novel Thioridazine Derivatives Active Against Drug-Resistant Tuberculosis, Eur. J. Med. Chem., 127, 147, 10.1016/j.ejmech.2016.12.042 Kigondu, 2014, Synthesis and Synergistic Antimycobacterial Screening of Chlorpromazine and Its Metabolites, Med. Chem. Commun., 5, 502, 10.1039/C3MD00387F Kigondu, 2014, Pharmacologically Active Metabolites, Combination Screening and Target Identification-Driven Drug Repositioning in Antituberculosis Drug Discovery, Bioorg. Med. Chem., 22, 4453, 10.1016/j.bmc.2014.06.012 Machado, 2018, Challenging the Drug-Likeness Dogma for New Drug Discovery in Tuberculosis, Front. Microbiol., 9, 1367, 10.3389/fmicb.2018.01367 Gupta, 2014, Efflux Inhibition With Verapamil Potentiates Bedaquiline in Mycobacterium Tuberculosis, Antimicrob. Agents Chemother., 58, 574, 10.1128/AAC.01462-13 Kumar, 2018, Reversed Isoniazids: Design, Synthesis and Evaluation Against Mycobacterium Tuberculosis, Bioorg. Med. Chem., 26, 833, 10.1016/j.bmc.2017.12.047 Bald, 2017, Targeting Energy Metabolism in Mycobacterium Tuberculosis, a New Paradigm in Antimycobacterial Drug Discovery, MBio, 8, e00272, 10.1128/mBio.00272-17 Kumar, 2016, Design, Synthesis, and Evaluation of Novel Hybrid Efflux Pump Inhibitors for Use Against Mycobacterium Tuberculosis, ACS Infect. Dis., 2, 714, 10.1021/acsinfecdis.6b00111 Wright, 2004, Generation of Resting Membrane Potential, Adv. Physiol. Educ., 28, 139, 10.1152/advan.00029.2004 Pieroni, 2015, Discovery of Antitubercular 2,4-Diphenyl-1H-Imidazoles From Chemical Library Repositioning and Rational Design, Eur. J. Med. Chem., 100, 44, 10.1016/j.ejmech.2015.05.048 Azzali, 2017, Substituted N-Phenyl-5-(2-(Phenylamino)Thiazol-4-Yl)Isoxazole-3-Carboxamides Are Valuable Antitubercular Candidates That Evade Innate Efflux Machinery, J. Med. Chem., 60, 7108, 10.1021/acs.jmedchem.7b00793 Pieroni, 2014, Design, Synthesis and Investigation on the Structure-Activity Relationships of N-Substituted 2-Aminothiazole Derivatives as Antitubercular Agents, Eur. J. Med. Chem., 72, 26, 10.1016/j.ejmech.2013.11.007 Machado, 2018, Adjuvant Therapies Against Tuberculosis: Discovery of a 2-Aminothiazole Targeting Mycobacterium Tuberculosis Energetics, Future Microbiol., 13, 1383, 10.2217/fmb-2018-0110 Lu, 2014, The ATP Synthase Inhibitor Bedaquiline Interferes With Small-Molecule Efflux in Mycobacterium Smegmatis, J. Antibiot. (Tokyo), 67, 835, 10.1038/ja.2014.74 Fan, 2018, Fluoroquinolone Derivatives and Their Anti-Tubercular Activities, Eur. J. Med. Chem., 146, 554, 10.1016/j.ejmech.2018.01.080